Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

Completed · Phase 1

Conditions studied: Advanced Prostate Adenocarcinoma

In brief

A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.

Key facts

Study ID

NCT00502164

Run by

AstraZeneca

People needed

40

Starts

2004-03-01

Last updated by the study team

2011-01-21

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men, 18yrs and older
• Histological or cytological confirmation of prostate adenocarcinoma (symptomatic or asymptomatic)
• Prior hormonal therapy, and/or no more than 1 prior chemotherapy regimen (including estramustine and/or corticosteroids) for treatment of prostate adenocarcinoma

You may not qualify if…

• Prior radiotherapy to bone metastases within 4 weeks prior to screening
• any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy
• Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable with steroid treatment for 1 week.

Where it is running

• Research Site — San Francisco, California, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.